VolitionRx Announces Acceptance of Compliance Plan by NYSE American
VolitionRx received acceptance from the NYSE American for its plan to regain compliance with continued listing standards, granting the company until August 6, 2027 to cure the deficiency. The exchange had notified the company in February that it failed to meet equity requirements due to reported losses in recent fiscal years and was ineligible for market cap exemptions.
Key figures
- Compliance deadline
- August 6, 2027
- Min equity 2yr losses
- $2.0 million
- Min equity 3yr losses
- $4.0 million
- Min equity 5yr losses
- $6.0 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.